Get Support

Search global stocks & ETFs...Ctrl K

Learn Mode

INSM - Insmed Inc

10

$115.62

-$2.37 (-2.009%)

At market close

$115.89

$0.27 (0.234%)

Pre Market 5/15/26, 10:26 AM

3.11/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

INSM

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$25.06B

Industry

Biotechnology

EPS (TTM)

-$5.49

P/E (TTM)

0.00

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

30.58

P/B

35.55

Diluted Shares

215.47M

Ex-Dividend

--

Next Earnings

08-05

Forward P/E

0.00

Payout Ratio

--

P/FCF (TTM)

0.00

FCF Yield

--

Earnings Yield

-4.72%

52 Week Range

Score Card

Explore Scores Tab

3.11

Average

Insmed Inc has a current cash runway of 15.93 months. The cash runway is the amount of time the business has at its current burn rate before it will need to take on debt or dilute shareholders to raise more money. However, it has grown revenue at 115.09% over the past year, which is strong growth.

Valuation Model

Key Score

3.00

Average

Management

5.00

Very Good

Growth

5.00

Very Good

Profitability

1.00

Very Bad

Fin. Health

2.00

Bad

Dividends

--

--

Analyst

2.00

Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

8 new filings were in the last 7 days

Filter Form Types

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-14 17:20:30

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-13 17:24:39

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-13 17:18:59

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-13 17:17:49

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-13 17:17:24

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-13 17:14:07

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-13 16:50:00

Form 144

Notice of proposed sale of securities pursuant to Rule 144

Filed on 2026-05-11 16:46:26

Form 8-K

Current report pursuant to Section 13 or 15(d)

Filed on 2026-05-07 07:01:37

Form 10-Q

General form for quarterly financial reports under Section 13 or 15(d)

Filed on 2026-05-07 07:00:34

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-05-06 16:11:30

Form SCHEDULE 13G

Unknown Form Type

Filed on 2026-05-06 11:23:35

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-04-25

High:

$255.15

120.7%

Avg:

$216.41

87.2%

Low:

$178.77

54.6%

(% change is relative to the current stock price: $115.62)

Analyst Recommendations

Go to Analyst Tab

4.29

Very Good

32%

Strong Buy (9)

64%

Buy (18)

4%

Hold (1)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://insmed.com/
Address
700 Us Highway 202/206, Bridgewater NEW JERSEY, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1104506

Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. The company is headquartered in Bridgewater, New Jersey and currently employs 1,664 full-time employees. The company is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.

IPO Date

1991-02-15

Industry

Biotechnology

Total Employees

1,664

Exchange

Nasdaq Nms - Global Market

Reporting Currency

USD

GICS

Biotechnology

GICS Sub

Biotechnology

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences